| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Zimmer Biomet Holdings, Inc.$91.34
+2.11 (+2.36%)
D 26Pipeline Score MedTech · Commercial
Market Cap
16.54 B
EPS
3.87
P/E Ratio
22.2 $
Value Trade
165.48 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.09 B
R&D Expenses
103.40 M
Operating CF
359.40 M
Total Assets
22.72 B
Total Liabilities
10.04 B
Equity
12.67 B
D/E Ratio
12,345
3 %
Week
-8.25 %
1 Month
-13.36 %
3 Month
-4.45 %
6 Month
-47.54 %
5 Year
198.76 %
All Time
Cash Data
Cash Position
424.20 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 1, 2026
Overview
Volume
1.54 M
52 Week Range
79.12 - 108.29
% held by Insiders
0.18 %
% held by Institutions
102.95 %
Enterprise Value
23.60 B
Total Shares
193.44 M
Short %
6.05 %
Float Shares
192.48 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D26
Pipeline Score $218M
Pipeline ValueValuation Signal
2
Drugs Scored0.0x
rNPV / MCap Top 26%
Mid Cap (rank 675 of 911)
Percentile RankZimmer Biomet Holdings, Inc. faces pipeline headwinds (26/100), with $257M risk-adjusted pipeline value, led by of cBMA aspirate into the index leg in Peripheral Artery Disease (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| of cBMA aspirate into the index leg Monoclonal antibody | Peripheral Artery Disease | Phase 1 | NCT02863926 | 16% | $154M | COMPLETED | 6 | - | - | Jul 27, 2018 | - | Dec 12, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZBH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ZBH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZBHZimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...
Zimmer Biomet Holdings, Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. The management team will engage in a fireside chat at 10:40 a.m. ET, which will be accessible via a live audio webcast. This event highlights Zimmer Biomet's ongoing commitment to innovation in medical technology.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the second quarter of 2026. The dividend is set to be paid on or about July 31, 2026, to shareholders on record as of June 25, 2026. This announcement underscores the company's ongoing commitment to delivering value to its shareholders.
Read more →ZBHZimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1...
Zimmer Biomet Holdings, Inc. has raised its share repurchase expectations to up to $1 billion for fiscal year 2026, an increase of $250 million from previous estimates. This decision is supported by the company's existing $1.5 billion share repurchase authorization. The actual timing and amount of repurchases will depend on market conditions and other financial considerations.
Read more →ZBHZimmer Biomet Increases Share Repurchase Expectations — Up to $1 Billion by Year End (WARSAW, Ind.)
Zimmer Biomet Holdings, Inc. has raised its share repurchase expectations from $750 million to up to $1 billion for fiscal year 2026. This decision, which comes under a previously approved $1.5 billion share repurchase authorization, reflects the company's approach to managing its capital and reserves. The actual timing and amount of the repurchases will be contingent on various factors such as market conditions and stock prices. Zimmer Biomet continues to emphasize its commitment to innovation and maintaining a strong portfolio in medical technology.
Read more →ZBHZimmer Biomet to Present at the BofA Securities 2026 Health Care Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...
Zimmer Biomet Holdings, Inc. will present at the Bank of America Securities Health Care Conference on May 13, 2026. The management team will participate in a fireside chat scheduled for 8:40 a.m. PT. A live audio webcast will be available on the company's Investor Relations website, with a replay option following the event.
Read more →ZBH▼ -10.6%on this news
Zimmer Biomet Announces Chief Financial Officer Transition Suketu Upadhyay to Depart; Paul Stellato Named Interim CFO (WARSAW, Ind.)
Zimmer Biomet Holdings, Inc. announced the departure of Chief Financial Officer Suketu Upadhyay, effective April 28, 2026. Paul Stellato has been named the interim CFO while the company searches for a permanent replacement. Stellato, who has over 20 years of finance experience, is expected to ensure continuity during this transition. The company remains focused on executing its strategy and delivering on its commitments despite this change in leadership.
Read more →ZBH▼ -10.6%on this news
Zimmer Biomet Announces First Quarter 2026 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2026. The Company reported first...
Zimmer Biomet Holdings, Inc. reported strong financial results for Q1 2026, with net sales of $2.087 billion, a 9.3% increase from the previous year. The company also saw a significant rise in diluted earnings per share, which reached $1.22, marking a 34.1% increase. Additionally, Zimmer Biomet updated its full-year financial guidance, reflecting confidence in its growth strategy and market performance. The company highlighted successful product launches and strategic initiatives contributing to its positive outlook.
Read more →ZBH▼ -10.6%on this news
Zimmer Biomet Announces Chief Financial Officer Transition Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced Suketu Upadhyay, Chief Financial Officer and...
Zimmer Biomet announced the departure of Chief Financial Officer Suketu Upadhyay, effective April 28, 2026, for a new opportunity. Paul Stellato, the current Controller and Chief Accounting Officer, has been named interim CFO while the company searches for a permanent successor. The company expressed gratitude for Upadhyay's contributions and confidence in Stellato's leadership during this transition.
Read more →ZBH▼ -10.6%on this news
Media Investors Troy Kirkpatrick David DeMartino 614-284-1926 646-531-6115 troy.kirkpatrick@zimmerbiomet.com david.demartino@zimmerbiomet.com Kirsten Fallon Zach Weiner 781-779-5561 908-591-6955 kirsten.fallon@zimmerbiom
Zimmer Biomet reported a strong first quarter of 2026, with net sales of $2.087 billion, marking a 9.3% increase year-over-year. The company also achieved diluted earnings per share of $1.22, which is a notable rise of 34.1%. Strategic advancements included the hiring of a new Chief Science, Technology and Medical Affairs Officer and the successful enrollment in a clinical study for a robotic knee arthroplasty system. Additionally, Zimmer Biomet is optimistic about raising its adjusted EPS guidance and free cash flow expectations for the year.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will ...
Zimmer Biomet Holdings, Inc. has announced a webcast for its first quarter earnings conference call scheduled for April 28, 2026. The call will provide insights into the company's financial performance and will be accessible via their Investor Relations website. A news release with detailed results will precede the call.
Read more →ZBHZimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik,...
Zimmer Biomet has appointed Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer, effective April 14. Dr. Vigdorchik, an experienced orthopedic surgeon, will oversee the company's technology portfolio, including AI and robotics. His leadership is expected to accelerate innovation and strengthen clinical engagement within the organization.
Read more →ZBHZimmer Biomet Wins Three Awards at Healthcare Asia Medtech Awards 2026 Zimmer Biomet (NYSE and SIX: ZBH), a global medical technology leader, today announced it received three awards at the Healthcare Asia Medtech Awards ...
Zimmer Biomet has been recognized with three awards at the Healthcare Asia Medtech Awards 2026 for its innovative contributions in orthopedic product development, digital health, and surgeon engagement. The company received accolades for its iodine-treated hip implant, the WalkAI recovery tracking platform, and its awareness campaign featuring Arnold Schwarzenegger. These awards highlight the company's commitment to improving patient outcomes across the Asia Pacific region.
Read more →ZBHZimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it will unveil new clinical and operational...
Zimmer Biomet will present new clinical data and innovations at the AAOS 2026 Annual Meeting. Arnold Schwarzenegger will serve as the Presidential Guest Speaker, discussing performance and teamwork. The company will showcase advanced orthopedic technologies, including robotics and AI-driven solutions, aimed at enhancing surgical precision and patient outcomes.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for First Quarter of 2026 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the first quarter of 2026. This dividend is set to be paid on or about April 30, 2026, to stockholders of record as of March 31, 2026. The announcement reflects the company's ongoing commitment to delivering value to its shareholders.
Read more →ZBHZimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant...
Zimmer Biomet reported strong financial results for Q4 and full-year 2025, with net sales rising 10.9% to $2.244 billion. However, diluted earnings per share fell 41.7% to $0.70, reflecting challenges in profitability. The company announced a new stock repurchase program and provided cautious guidance for 2026, citing a transition to a specialized sales organization. Positive developments include FDA clearance for a key product upgrade and strategic acquisitions.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2025 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its fourth quarter earnings conference call...
Zimmer Biomet Holdings, Inc. has announced its fourth quarter earnings conference call scheduled for February 10, 2026, at 8:30 a.m. ET. A news release with detailed financial results will be available earlier that day. The call can be accessed via their Investor Relations website and will also be available for replay.
Read more →ZBHZimmer Biomet to Present at the 44th Annual J.P. Morgan Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...
Zimmer Biomet Holdings, Inc. announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be accessible via a live webcast on their Investor Relations website, which will also be archived for later viewing. The company emphasizes its commitment to innovation and improving patient experiences.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2025 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the fourth quarter of 2025. This dividend is set to be paid on or about January 30, 2026, to stockholders recorded by December 30, 2025. The announcement underscores the company's ongoing commitment to shareholder value.
Read more →ZBHZimmer Biomet, OneStep Collaborate to Provide Enhanced Mobility Data to Patients and Surgeons to Help Improve Joint Procedure Recovery Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and OneStep, the FDA-listed digital fall prevention and...
Zimmer Biomet and OneStep have announced a collaboration to integrate OneStep's mobility analytics into Zimmer Biomet's mymobility Care Management Platform. This partnership aims to provide comprehensive mobility data to enhance recovery monitoring for orthopedic surgery patients. The integration will allow for remote assessment of patient mobility, empowering both patients and surgeons in the recovery process.
Read more →ZBHZimmer Biomet Receives U.S. FDA Clearance for Enhanced Version of ROSA® Knee Robotic Technology Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k)...
Zimmer Biomet has received FDA 510(k) clearance for its ROSA Knee with OptimiZe, an enhanced robotic-assisted knee surgery system. This version offers personalized surgical planning and features designed to improve accuracy and reduce variability during procedures. The system integrates with ZB Edge Analytics for data-driven decisions. Commercial release is anticipated in early 2026.
Read more →ZBHZimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...
Zimmer Biomet Holdings, Inc. will present at the Annual Jefferies Global Healthcare Conference in London on November 18, 2025. The presentation will be accessible via a live webcast on the company's Investor Relations website. Zimmer Biomet emphasizes its commitment to innovation in medical technology, enhancing patient experience through advanced solutions.
Read more →ZBH▼ -15.1%on this newsshared move
Zimmer Biomet Announces Third Quarter 2025 Financial Results Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant...
Zimmer Biomet reported strong financial results for Q3 2025, with net sales reaching $2.001 billion, a 9.7% increase from the previous year. The company also saw a rise in diluted earnings per share to $1.16, with adjusted earnings at $1.90. Despite strong performance in the U.S., challenges in Latin America and Emerging Markets were noted. The company is set to launch new technologies, including a fully autonomous orthopedic robot.
Read more →ZBHZimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the U.S. Food and Drug Administration (FDA) has ...
Zimmer Biomet has received FDA Breakthrough Device Designation for its iodine-treated total hip replacement system, marking a significant milestone as the first product in the company's history to achieve this status. This innovative technology aims to reduce infection risks associated with joint replacements, particularly for patients at higher risk. The system has already been approved in Japan, showcasing its potential to improve patient outcomes significantly.
Read more →ZBHZimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting bold innovations across ...
Zimmer Biomet is showcasing its innovative robotics and musculoskeletal products at the 2025 AAHKS Annual Meeting. The company emphasizes its comprehensive hip and knee portfolios, including the newly acquired mBôs™ robotic system. CEO Ivan Tornos highlights the urgency for advanced surgical solutions as patient expectations rise. The booth features various digital and robotic technologies aimed at improving surgical precision and patient outcomes.
Read more →ZBHZimmer Biomet Launches Two New Foot and Ankle Solutions for Complex Trauma Cases Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, a wholly owned subsidiary, today announced the...
Zimmer Biomet has launched two new solutions aimed at addressing complex foot and ankle trauma: the Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail. These products enhance treatment options for challenging injuries, particularly pilon fractures and hindfoot injuries. The launch reflects the company's dedication to innovation in orthopedic solutions.
Read more →ZBHZimmer Biomet Completes Acquisition of Monogram Technologies Transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonom
Zimmer Biomet has announced the completion of its acquisition of Monogram Technologies, enhancing its portfolio in orthopedic robotics and navigation. This acquisition positions Zimmer Biomet to potentially become the first orthopedic company to offer fully autonomous robotic solutions. Monogram's technologies are expected to bolster Zimmer Biomet's existing product offerings, aiming to address needs across various surgical procedures. However, integrating Monogram's capabilities poses challenges and risks, particularly regarding the realization of anticipated benefits and achieving regulatory milestones.
Read more →ZBHZimmer Biomet Completes Acquisition of Monogram Technologies Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ("Zimmer Biomet"), a global medical technology leader, today announced it has completed the...
Zimmer Biomet has completed its acquisition of Monogram Technologies, enhancing its orthopedic robotics portfolio. This acquisition introduces semi- and fully autonomous robotic technologies, aiming to provide surgeons with advanced solutions. The integration of Monogram's capabilities is expected to accelerate innovation and strengthen Zimmer Biomet's market position. The commercialization of Monogram's technology is anticipated by early 2027.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of Third Quarter 2025 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, ...
Zimmer Biomet Holdings, Inc. has announced that its third quarter earnings conference call will take place on November 5, 2025, at 8:30 a.m. ET. A news release detailing the quarterly results will be available earlier that day at 6:30 a.m. ET. The call will be accessible via a live audio webcast and will also be available for replay.
Read more →ZBHZimmer Biomet Announces Japan PMDA Approval of World's First Iodine-Treated Total Hip Replacement System Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the Pharmaceutical and Medical Devices Agency...
Zimmer Biomet has received approval from Japan's PMDA for the iTaperloc Complete and iG7 Hip System, the first orthopedic implants utilizing iodine technology. This innovation aims to reduce the risk of periprosthetic joint infection (PJI) by preventing bacterial adhesion. The approval enhances Zimmer Biomet's infection management solutions and underscores their commitment to advancing orthopedic technology.
Read more →ZBHZimmer Biomet to Showcase Foot and Ankle Portfolio at the American Orthopedic Foot and Ankle Society Annual Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its participation in the American Orthopedic...
Zimmer Biomet will participate in the AOFAS Annual Conference from September 10-13, 2025, showcasing its Paragon 28 foot and ankle portfolio. The company aims to highlight innovations that enhance surgical outcomes for patients with foot and ankle conditions. Attendees can experience hands-on training and discussions on the latest advancements in foot and ankle surgery.
Read more →ZBHZimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, ...
Zimmer Biomet has appointed Dr. Jonathan M. Vigdorchik and Dr. Anand M. Murthi as Chief Medical Advisors to enhance its musculoskeletal care initiatives. Dr. Vigdorchik will focus on Adult Reconstruction and Hip Implants, while Dr. Murthi will oversee Shoulder, Sports, Extremities, and Trauma. Their extensive clinical experience aims to guide product development and medical education efforts.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Third Quarter of 2025 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the third quarter of 2025. The dividend will be payable on or about October 31, 2025, to stockholders of record by September 30, 2025. This decision reflects the company's ongoing commitment to returning value to its shareholders.
Read more →ZBHZimmer Biomet to Present at the Annual Morgan Stanley Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Annual...
Zimmer Biomet Holdings, Inc. will present at the Annual Morgan Stanley Healthcare Conference on September 8, 2025. The presentation will be accessible via a live webcast on their Investor Relations website. The company emphasizes its commitment to innovation and improving patient experiences through advanced technologies.
Read more →ZBH▲ +8%on this news
Zimmer Biomet Announces Second Quarter 2025 Financial Results Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant...
Zimmer Biomet reported a 7.0% increase in net sales for Q2 2025, reaching $2.077 billion. Adjusted earnings per share rose by 3.0% to $2.07. The company has tightened its full-year revenue growth guidance and announced the acquisition of Monogram Technologies to enhance its robotics offerings. Despite these positives, diluted earnings per share fell compared to the previous year, and operating profit margins decreased.
Read more →ZBH▲ +8%on this news
Media Investors Kristen Cardillo David DeMartino (925) 786-4913 (646) 531-6115 kristen.cardillo@zimmerbiomet.com david.demartino@zimmerbiomet.com Kirsten Fallon Zach Weiner (781) 779-5561 (908) 591-6955 kirsten.fallon@zi
Zimmer Biomet announced its second quarter 2025 financial results, reporting net sales of $2.077 billion, a 7.0% increase from the previous year. The company's adjusted diluted earnings per share rose by 3.0% to $2.07. As part of its growth strategy, Zimmer Biomet is tightening its revenue growth guidance for the full year to between 6.7% and 7.7% and increasing its adjusted EPS forecast to $8.10 - $8.30. Notably, they also announced plans to acquire Monogram Technologies, enhancing their capabilities in surgical robotics.
Read more →ZBHZimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ: MGRM), an orthopedic...
Zimmer Biomet has announced a definitive agreement to acquire Monogram Technologies for approximately $177 million. This acquisition aims to enhance Zimmer Biomet's orthopedic robotics capabilities, particularly through Monogram's semi- and fully autonomous robotic technologies. The deal is expected to contribute to revenue growth starting in 2027 and is projected to be neutral to adjusted earnings per share in the initial years.
Read more →ZBHDisclaimer Cautionary Note Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1
Zimmer Biomet (ZBH) recently issued a disclaimer regarding its acquisition of Monogram Technologies Inc., emphasizing that the presentation includes forward-looking statements. Significant risks are associated with the transaction, including potential delays in receiving necessary regulatory approvals and the chance of competing acquisition proposals. Additionally, the expected benefits of the acquisition may not be fully realized, which could impact the companies' financial performance. The transaction is currently subject to various uncertainties and stipulations detailed in their SEC filings.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7,...
Zimmer Biomet Holdings, Inc. has announced a webcast for its second quarter earnings conference call scheduled for August 7, 2025. The call will begin at 8:30 a.m. ET, with a news release available earlier that day. Investors can access the live audio via the company's Investor Relations website.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the second quarter of 2025. This dividend is set to be paid on or about July 31, 2025, to stockholders of record by June 26, 2025. The announcement underscores the company's ongoing commitment to its shareholders.
Read more →ZBHZimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group...
Zimmer Biomet has appointed Kevin Thornal as Group President for Global Businesses and the Americas, effective July 1, 2025. Thornal, with over 20 years of experience in medical technology, is expected to enhance the company's performance and commercial strategy. He previously led significant growth at Nevro Corp. and Hologic, Inc. His leadership is anticipated to drive innovation and improve patient outcomes.
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski David DeMartino 445-248-0577 646-531-6115 heather.zoumaslubeski@zimmerbiomet.com david.demartino@zimmerbiomet.com Zach Weiner 908-5
Zimmer Biomet Holdings, Inc. has appointed Kevin Thornal as Group President for Global Businesses and the Americas, effective from July 1, 2025. He will oversee Zimmer Biomet's commercial organization and spearhead business strategies across several key units. Thornal brings over 20 years of experience in the medical technology space, including leadership during significant growth periods and product launches at Nevro Corp. and Hologic, Inc. His expectation is to advance Zimmer Biomet's mission of improving musculoskeletal health through innovative solutions.
Read more →ZBHZimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Goldman...
Zimmer Biomet Holdings, Inc. will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025. The management team will discuss the company's innovative medical technologies aimed at improving patient mobility and health. A live webcast of the presentation will be available on their Investor Relations website.
Read more →ZBH▼ -11.6%on this news
Zimmer Biomet Announces First Quarter 2025 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025. The Company reported first...
Zimmer Biomet Holdings, Inc. reported first quarter 2025 financial results, showcasing a 1.1% increase in net sales to $1.909 billion. The company also updated its full-year revenue guidance following the acquisition of Paragon 28. Despite a slight decrease in diluted earnings per share, the company remains optimistic about growth driven by new product innovations and a strong portfolio in the U.S. hips market.
Read more →ZBH▼ -11.6%on this news
Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 heather.zoumaslubeski@zimmerbiomet.com david.demartino@zimmerbiomet.com Zach Weiner (908) 591-6955 zach.weiner@zimmerbiomet.com Zimmer
Zimmer Biomet announced its first quarter 2025 financial results, revealing a 1.1% increase in net sales, reaching $1.909 billion. The company has updated its full-year revenue guidance to account for the recent acquisition of Paragon 28, boosting its growth potential in the foot and ankle market. Additionally, it showcased several innovative products at the recent AAOS meeting and received FDA clearance for a new knee implant. However, some product categories exhibited declines, impacting overall growth projections.
Read more →ZBHZimmer Biomet: Media Heather Zoumas-Lubeski 445-248-0577 heather.zoumaslubeski@zimmerbiomet.com Kirsten Fallon 781-779-5562 kirsten.fallon@zimmerbiomet.com Investors David DeMartino 646-531-6115 david.demartino@zimmerbio
Zimmer Biomet announced the completion of its acquisition of Paragon 28, a medical device company specializing in foot and ankle orthopedics. This acquisition aims to enhance Zimmer Biomet's offerings and strengthen its position in a rapidly growing market segment. The transaction is expected to drive innovation and growth while capitalizing on Paragon 28's specialized sales organization. However, there are risks associated with successfully integrating Paragon 28 and achieving projected revenue milestones related to contingent value rights.
Read more →ZBHZimmer Biomet Completes Acquisition of Paragon 28 Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the...
Zimmer Biomet has completed the acquisition of Paragon 28, enhancing its position in the growing foot and ankle orthopedic market. This acquisition is expected to drive innovation and expand Zimmer Biomet's offerings while leveraging Paragon 28's specialized sales organization. The deal includes cash compensation and contingent value rights based on revenue milestones.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025,...
Zimmer Biomet Holdings, Inc. announced that it will host a webcast for its first quarter earnings conference call on May 5, 2025. The call will begin at 8:30 a.m. ET, with a news release available earlier that day. Investors can access the live audio and replay through the company's Investor Relations website.
Read more →ZBHZimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announced its RibFix Advantage® Fixation System has...
Zimmer Biomet has announced that its RibFix Advantage Fixation System has received CE Mark certification, marking it as the first intrathoracic rib fixation system to achieve this designation. This system allows for minimally invasive fixation and stabilization of rib fractures, potentially reducing soft tissue disruption compared to traditional methods. The company aims to support evolving surgical needs in the European Economic Area and other CE Mark-recognizing markets.
Read more →ZBHZimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio...
Zimmer Biomet is showcasing its diverse orthopedic and musculoskeletal innovations at the AAOS 2025 Annual Meeting. Key highlights include the Z1 Triple-Taper Femoral Hip System, the Persona Revision Solution Femur, and the debut of ZBX Ambulatory Surgery Center solutions. The company emphasizes its commitment to enhancing surgical efficiency and patient outcomes through innovative technologies.
Read more →ZBHZimmer Biomet Receives FDA Clearance for Persona® Revision SoluTion™ Femur Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k)...
Zimmer Biomet has received FDA 510(k) clearance for its Persona Revision SoluTion Femur, a knee implant designed for patients with metal sensitivities. This innovative product offers a metal-free alternative, addressing the needs of those who may experience adverse reactions to common metals used in implants. The Persona Revision SoluTion Femur will be available in the U.S. starting Q3 2025.
Read more →ZBHZimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior...
Zimmer Biomet has appointed Kristen Cardillo as Senior Vice President and Chief Communications Officer, effective March 10, 2025. She will lead the company's global communications strategy, aiming to strengthen stakeholder engagement and enhance the company's brand in the MedTech sector. Cardillo previously held senior communications roles at 10x Genomics and Becton, Dickinson and Company.
Read more →ZBHZimmer Biomet to Present at the 27th Annual Barclays Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 27th...
Zimmer Biomet Holdings, Inc. will present at the 27th Annual Barclays Healthcare Conference on March 13, 2025. The presentation will be accessible via a live webcast on their Investor Relations website, which will also be archived for later viewing. This event highlights the company's ongoing commitment to innovation in medical technology.
Read more →ZBHZimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as...
Zimmer Biomet has appointed Jehanzeb Noor as Senior Vice President and Chief Strategy, Innovation and Business Development Officer. Noor will oversee strategy development, M&A activities, and product development, including the integration of the pending acquisition of Paragon 28. His previous roles include leadership positions at Trivium and Smiths Medical.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for First Quarter of 2025 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the first quarter of 2025. The dividend is payable on or about April 30, 2025, to stockholders of record as of March 31, 2025. This decision showcases the company's commitment to returning value to its shareholders.
Read more →ZBHZimmer Biomet Launches You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the launch of the You'll Be Back campaign with...
Zimmer Biomet has launched the 'You'll Be Back' campaign, led by Chief Movement Officer Arnold Schwarzenegger, to support individuals living with joint pain. The initiative aims to create an online community where participants can share their experiences and connect with healthcare professionals. The campaign addresses the widespread issue of joint pain and encourages proactive health management.
Read more →ZBHZimmer Biomet Announces Upcoming Changes to Company's Board of Directors Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of...
Zimmer Biomet Holdings, Inc. announced changes to its Board of Directors, including the retirement of Non-Executive Chairman Christopher Begley and the appointment of Ivan Tornos as Chairman. Michael Farrell will take on the role of Lead Independent Director. The leadership changes are expected to enhance the company's strategic direction and value creation.
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 heather.zoumaslubeski@zimmerbiomet.com david.demartino@zimmerbiomet.com Zach Weiner (
Zimmer Biomet announced changes to its Board of Directors, including the retirement of Chris Begley, who served since 2012 and was instrumental in the company’s success. Ivan Tornos has been appointed as the new Chairman of the Board, while Mick Farrell takes on the role of Lead Independent Director. Both appointments highlight a commitment to strong leadership and strategic oversight as the company aims to enhance its value for stakeholders.
Read more →ZBH▼ -5.1%on this news
Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024. The Company...
Zimmer Biomet Holdings, Inc. reported strong financial results for Q4 and full-year 2024, with net sales reaching $2.023 billion and $7.679 billion respectively. The company announced a strategic acquisition of Paragon 28, enhancing its focus on the foot and ankle segment. Additionally, FDA approvals for new products were highlighted, reflecting ongoing innovation.
Read more →ZBHZimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, Inc. (NYSE: FNA), a leading medical device...
Zimmer Biomet has announced a definitive agreement to acquire Paragon 28 for approximately $1.1 billion. This acquisition aims to expand Zimmer Biomet's presence in the $5 billion foot and ankle market, enhancing its financial profile and revenue growth. The deal is expected to be accretive to adjusted EPS within 24 months, despite initial dilution. Closing is contingent on regulatory approvals and stockholder consent.
Read more →ZBHExecution Version VOTING AGREEMENT This VOTING AGREEMENT (this Agreement ), dated as of
Zimmer, Inc. has entered into a Voting Agreement with its stockholders in relation to the proposed merger with Paragon 28, Inc. The agreement mandates that stockholders vote in favor of the merger and refrain from actions that could impede the transaction. This structured approach intends to facilitate a smooth merger process and holds stockholders accountable for their shares' votes. The agreement also outlines provisions for irrevocable proxies to ensure compliance.
Read more →ZBHZimmer Biomet: Media Investors Heather Zoumas-Lubeski 445-248-0577 heather.zoumaslubeski@zimmerbiomet.com Kirsten Fallon 781-779-5562 kirsten.fallon@zimmerbiomet.com David DeMartino 646-531-6115 david.demartino@zimmerbio
Zimmer Biomet Holdings, Inc. has announced its definitive agreement to acquire Paragon 28, a company focused on the foot and ankle orthopedic segment, for approximately $1.1 billion. The acquisition is expected to enhance Zimmer Biomet's financial profile, be immediately accretive to revenue growth, and add new product offerings to their portfolio. Paragon 28 aims to leverage its innovative solutions to maximize patient outcomes, marking a significant step for Zimmer Biomet into a high-growth market. The transaction is subject to regulatory approvals and is anticipated to close in the first half of 2025.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2024 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, ...
Zimmer Biomet Holdings, Inc. announced that it will host a webcast for its fourth quarter earnings conference call on February 6, 2025. The call will begin at 8:30 a.m. ET, with a news release available earlier that day. The company emphasizes its commitment to innovation and quality in medical technology.
Read more →ZBHZimmer Biomet to Present at the 43rd Annual J.P. Morgan Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43rd...
Zimmer Biomet Holdings, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation will be accessible via a live webcast, which will also be archived for later viewing. This event highlights the company's ongoing commitment to innovation in medical technology.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2024 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the fourth quarter of 2024. This dividend will be payable on January 31, 2025, to stockholders of record as of December 30, 2024. The announcement reflects the company's ongoing commitment to its shareholders and highlights its stability in the medical technology sector.
Read more →ZBHZimmer Biomet Receives FDA Clearance for OsseoFit™ Stemless Shoulder System for Total Shoulder Replacement Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k)...
Zimmer Biomet has received FDA 510(k) clearance for its OsseoFit Stemless Shoulder System, designed for total shoulder replacement. This innovative system aims to match the natural anatomy of the humerus, promoting bone preservation and stable fixation. The product will be commercially available in Q1 2025, enhancing Zimmer Biomet's shoulder portfolio.
Read more →ZBHZimmer Biomet Receives FDA Clearance for Persona® SoluTion™ PPS® Femur Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k)...
Zimmer Biomet has received FDA 510(k) clearance for its Persona SoluTion PPS Femur, a total knee implant designed for patients with sensitivities to metal and bone cement. This new component features a porous coating for cementless fixation and is part of a comprehensive knee system. The product is set to be commercially available in the U.S. in Q1 2025.
Read more →ZBHZimmer Biomet Receives FDA Approval for Oxford® Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S. Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA)...
Zimmer Biomet has received FDA approval for the Oxford Cementless Partial Knee, marking it as the only cementless partial knee replacement implant approved in the U.S. This innovative implant is based on extensive clinical data and is designed to improve surgical efficiency and long-term outcomes. The launch is set for Q1 2025, addressing a significant demand in the U.S. market.
Read more →ZBHZimmer Biomet to Present at Citi's 2024 Global Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Citi...
Zimmer Biomet Holdings, Inc. will participate in the Citi Global Healthcare Conference on December 5, 2024, featuring a fireside chat at 8:45 a.m. ET. The event will be accessible via a live webcast on the company's Investor Relations website, which will also archive the presentation for later viewing. This participation highlights Zimmer Biomet's ongoing commitment to innovation and leadership in the medical technology sector.
Read more →ZBHZimmer Biomet Announces CE Mark Certification for Persona® Revision Knee System Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee...
Zimmer Biomet has received CE Mark certification for its Persona Revision Knee System, enhancing its availability in Europe. This innovative system is designed for revision knee arthroplasty, offering personalized fit and optimized function. The launch supports Zimmer Biomet's commitment to improving patient outcomes and alleviating pain through advanced medical technology.
Read more →ZBHZimmer Biomet to Present at Jefferies London Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Jefferies...
Zimmer Biomet Holdings, Inc. announced its participation in the Jefferies London Healthcare Conference scheduled for November 19, 2024. The management team will engage in a fireside chat at 11:00 a.m. GMT. Investors can access a live webcast of the presentation, which will also be archived for later viewing.
Read more →ZBH▲ +5.7%on this news
Zimmer Biomet Announces Third Quarter 2024 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2024. The Company reported...
Zimmer Biomet reported third quarter 2024 financial results, showing a 4.0% increase in net sales to $1.824 billion. Despite facing ERP implementation challenges, the company remains optimistic about its innovation pipeline and upcoming product launches. However, it has updated its financial guidance for the year, indicating a more conservative outlook.
Read more →ZBHZimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced plans for the broad commercial launch of the...
Zimmer Biomet announced the upcoming launch of the Z1 Femoral Hip System at the 2024 AAHKS Annual Meeting. This new system is designed for total hip arthroplasty and is paired with the established G7 Acetabular System. Positive clinical data on the G7 system will also be presented, highlighting its safety and durability. The company aims to enhance surgical efficiency and outcomes through innovative technologies.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of Third Quarter 2024 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, October 30, ...
Zimmer Biomet Holdings, Inc. has announced a webcast for its third quarter earnings conference call scheduled for October 30, 2024. The call will begin at 8:30 a.m. ET, with a news release available earlier that day. Investors can access the live audio via the company's Investor Relations website, and a replay will be provided post-call.
Read more →ZBH▼ -8.7%on this news
Zimmer Biomet Names David DeMartino as Senior Vice President, Investor Relations Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that David DeMartino will join the Company as...
Zimmer Biomet has appointed David DeMartino as Senior Vice President of Investor Relations, effective September 9, 2024. He will report to CEO Ivan Tornos and is tasked with leading the company's investor relations strategy. DeMartino has over 25 years of experience in the healthcare sector, including roles in asset management and equity research.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the third quarter of 2024. This dividend is set to be paid on or about October 31, 2024, to stockholders of record by September 30, 2024. The announcement underscores the company's commitment to returning value to its shareholders.
Read more →ZBHZimmer Biomet to Present at the Wells Fargo 2024 and Morgan Stanley Annual Global Healthcare Conferences Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...
Zimmer Biomet Holdings, Inc. announced that its management team will present at the Wells Fargo 2024 Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference in September 2024. The presentations will highlight the company's innovative medical technologies. Live webcasts will be accessible on their Investor Relations website, with replays available afterward.
Read more →ZBHMedia Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Second Quarter 2024 Financial Results •
Zimmer Biomet Holdings, Inc. has announced its financial results for the second quarter of 2024, reporting net sales of $1.942 billion, an increase of 3.9% compared to the same period last year. Adjusted diluted earnings per share stood at $2.01. The company also updated its revenue guidance for 2024, reflecting currency expectations, but reaffirmed its constant currency revenue growth target. Notably, Zimmer Biomet announced its acquisition of OrthoGrid Systems to expand its surgical solutions in the hip replacement market.
Read more →ZBHcan be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of our Annual Report on Form 10-K for the year ended
The article references management's discussion and analysis of financial conditions as outlined in Zimmer Biomet's (ZBH) annual report on Form 10-K. It mainly emphasizes various financial linkages but does not provide substantial updates or insights on operations or recent developments. The content appears to focus on compliance with reporting standards without disclosing more detailed or actionable information for stakeholders.
Read more →ZBHZimmer Biomet Announces Second Quarter 2024 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2024. The Company reported second...
Zimmer Biomet Holdings, Inc. reported a strong second quarter for 2024, with net sales of $1.942 billion, reflecting a 3.9% increase from the previous year. The company reaffirmed its 2024 revenue guidance while announcing a strategic acquisition of OrthoGrid Systems to enhance its hip portfolio. Additionally, Zimmer Biomet was recognized as one of America's Best Midsize Companies of 2024.
Read more →ZBHZimmer Biomet Signs Definitive Agreement to Acquire OrthoGrid Systems, Inc. Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it signed a definitive agreement to...
Zimmer Biomet has signed a definitive agreement to acquire OrthoGrid Systems, enhancing its hip portfolio with AI-driven surgical guidance technology. The acquisition includes OrthoGrid's Hip AI platform and additional FDA-cleared applications, aimed at improving surgical accuracy and efficiency. The deal is expected to close by the end of Q4 2024, pending customary conditions.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of Second Quarter 2024 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Wednesday, August 7,...
Zimmer Biomet Holdings, Inc. has announced its second quarter earnings conference call scheduled for August 7, 2024, at 8:30 a.m. ET. A news release with detailed results will be available earlier that day. The call can be accessed via their Investor Relations website, and international callers have specific dialing instructions.
Read more →ZBHMedia Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Dir
Zimmer Biomet has appointed Devdatt Kurdikar to its Board of Directors, effective immediately. Kurdikar currently serves as the President and CEO of Embecta Corp. and has a strong background in medical technology and leadership. His experience includes a history at Becton, Dickinson and Company and Cardiac Science. The company anticipates that his expertise will support its mission to alleviate pain and improve lives.
Read more →ZBHZimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief...
Zimmer Biomet has appointed Devdatt Kurdikar to its Board of Directors, effective immediately. Kurdikar, currently the CEO of Embecta Corp, brings significant experience in medical technology and leadership. His expertise is expected to support Zimmer Biomet's mission to alleviate pain and enhance patient care. The company emphasizes its commitment to innovation and quality solutions.
Read more →ZBHZimmer Biomet Enters Distribution Agreement with THINK Surgical to Offer TMINI® Miniature Handheld Robotic System for Total Knee Arthroplasty Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a limited distribution agreement with THINK...
Zimmer Biomet has entered a limited distribution agreement with THINK Surgical to offer the TMINI Miniature Handheld Robotic System for total knee arthroplasty. This system complements Zimmer's existing ROSA Robotics portfolio, providing surgeons with more options for robotic assistance during knee replacement surgeries. The TMINI system is expected to be introduced in select U.S. markets in the second half of 2024.
Read more →ZBHZimmer Biomet to Present at the Goldman Sachs 45th Annual Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...
Zimmer Biomet Holdings, Inc. announced that its management team will present at the Goldman Sachs 45th Annual Healthcare Conference on June 11, 2024. The presentation will be accessible via a live webcast on the company's Investor Relations website. Zimmer Biomet emphasizes its commitment to innovation and improving patient health through advanced technologies.
Read more →ZBHZimmer Biomet Outlines Strategy to Deliver Above Market Growth at 2024 Investor Day Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today hosted its 2024 Investor Day and provided an in-depth...
Zimmer Biomet hosted its 2024 Investor Day, presenting a strategic plan aimed at achieving above-market growth through 2027. The company emphasized its focus on customer-centric solutions and announced a partnership with CBRE to develop orthopedic ambulatory surgery centers. Additionally, Zimmer Biomet plans to return a significant portion of free cash flow to shareholders.
Read more →ZBHZimmer Biomet Announces 2024 Investor Day Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it will host an Investor Day on Wednesday, ...
Zimmer Biomet Holdings, Inc. has announced an Investor Day scheduled for May 29, 2024, at the New York Stock Exchange. The event will include presentations from senior management, a surgeon panel discussion, and Q&A sessions. Attendees will also have the opportunity to view a product showcase. The event will be webcast for broader accessibility.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the second quarter of 2024. This dividend is set to be paid on or about July 31, 2024, to stockholders of record as of June 26, 2024. The announcement underscores the company's commitment to returning value to its shareholders.
Read more →ZBHZimmer Biomet Publishes 2023 Sustainability Report Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today published its 2023 Sustainability Report which provides...
Zimmer Biomet has released its 2023 Sustainability Report, showcasing its commitment to environmental, social, and governance (ESG) initiatives. The report details the company's goals to achieve Net-Zero greenhouse gas emissions by 2050, aligning with recognized sustainability frameworks. It also emphasizes advancements in product quality, safety, and employee development.
Read more →ZBHMedia Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces First Quarter 2024 Financial Results • F
Zimmer Biomet has reported a strong start to 2024, with first quarter net sales reaching $1.889 billion, marking a 3.2% increase from the previous year. The company also reported diluted earnings per share of $0.84, with an adjusted figure of $1.94. Notably, Zimmer Biomet received FDA clearances for the ROSA Shoulder System and the Z1 Femoral Hip Stem, showcasing its commitment to innovation. The company has reiterated its full-year financial guidance and emphasized ongoing efforts in health equity and workplace diversity.
Read more →ZBHZimmer Biomet Announces First Quarter 2024 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2024. The Company reported first...
Zimmer Biomet reported first quarter 2024 financial results, showing a 3.2% increase in net sales to $1.889 billion. The company also received FDA clearances for new products and reiterated its financial guidance for the year. However, diluted earnings per share fell to $0.84, and the operating profit margin decreased.
Read more →ZBHZimmer Biomet Becomes First and Only Official Medical Device Partner of Association of Pickleball Players, Professional Pickleball Association, and USA Pickleball Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced partnerships with three top pickleball...
Zimmer Biomet has announced its partnership with three major pickleball organizations, becoming the first official medical device partner for the sport. This collaboration aims to enhance joint health education and support the growing pickleball community, which includes over 48 million players. The company will also sponsor several key events, promoting awareness of joint health.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of First Quarter 2024 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Thursday, May 2, 2024...
Zimmer Biomet Holdings, Inc. has announced that its first quarter earnings conference call will take place on May 2, 2024, at 8:30 a.m. ET. A news release detailing the quarterly results will be available earlier that day. The call will be accessible via their Investor Relations website and will be available for replay afterward.
Read more →ZBHZimmer Biomet Receives FDA Clearance for ROSA® Shoulder System - the World's First Robotic Assistant for Shoulder Replacement Surgery Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k)...
Zimmer Biomet has received FDA clearance for the ROSA® Shoulder System, marking it as the first robotic surgical assistant for shoulder replacement surgery. This innovative system aims to enhance surgical precision and efficiency, integrating advanced digital technologies to support surgeons. The ROSA Shoulder will be commercially available in the U.S. in the second half of 2024.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for First Quarter of 2024 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the first quarter of 2024. This dividend will be payable on or about April 30, 2024, to stockholders of record as of March 29, 2024. The announcement reflects the company's ongoing commitment to delivering value to its shareholders.
Read more →ZBHZimmer Biomet Signs Global Health Equity Network's Zero Health Gaps Pledge and Expands Longstanding Commitment to Advancing Health Equity Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, signed the Global Health Equity Network's (GHEN) Zero Health...
Zimmer Biomet has signed the Global Health Equity Network's Zero Health Gaps Pledge, committing to integrate health equity into its core strategies. The company has established a Health Equity division to address disparities in orthopaedic care and improve access to quality medical services. This initiative includes forming partnerships and creating a Community Centered Care framework to support underserved communities.
Read more →ZBHZimmer Biomet Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is showcasing the latest innovations...
Zimmer Biomet is presenting its latest innovations at the AAOS 2024 Annual Meeting in San Francisco. Key highlights include the upcoming ROSA Robotics application for shoulder replacement, the Persona OsseoTi Keel Tibia for knee replacement, and the HAMMR Automatic Hip Impaction System. The company aims to improve surgical outcomes and enhance the clinician experience with its advanced technologies.
Read more →ZBHZimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2023. The Company...
Zimmer Biomet Holdings, Inc. reported strong financial results for Q4 and full-year 2023, with net sales reaching $1.940 billion in the fourth quarter and $7.394 billion for the year. The company also provided optimistic financial guidance for 2024, projecting revenue growth between 4.5% and 5.5%. Recent highlights include the closure of an FDA Warning Letter and the introduction of new automated surgical instruments.
Read more →ZBHMedia Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Res
Zimmer Biomet reported its fourth quarter and full-year 2023 financial results, highlighting a net sales increase of 6.3% in Q4 and 6.5% for the full year. The company achieved fourth quarter diluted earnings per share of $2.01 and adjusted earnings of $2.20. Additionally, Zimmer Biomet provided financial guidance for 2024, indicating projected revenue growth of 4.5% to 5.5%. The company has also made strategic moves including addressing an FDA warning letter and launching new automated surgical instruments.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2023 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 8, ...
Zimmer Biomet Holdings, Inc. has announced that its fourth quarter earnings conference call will be webcast on February 8, 2024. A news release with detailed results will be available earlier that day. Additionally, the company will host an in-person product showcase at the American Academy of Orthopaedic Surgeons Conference on February 13, 2024.
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announc
Zimmer Biomet Holdings, Inc. has announced the appointment of Louis A. Shapiro to its Board of Directors, effective immediately. Shapiro, previously President and CEO of the Hospital for Special Surgery, brings significant leadership experience in the healthcare sector. His background in managing a top-ranked orthopedic hospital aligns with Zimmer Biomet's mission to improve health outcomes. The company remains focused on innovation and the patient experience within the medical technology landscape.
Read more →ZBHZimmer Biomet Announces Appointment of Louis A. Shapiro to Board of Directors Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Louis A. Shapiro, formerly the President...
Zimmer Biomet has appointed Louis A. Shapiro to its Board of Directors. Shapiro, who previously served as President and CEO of the Hospital for Special Surgery, brings significant leadership experience in the healthcare sector. His appointment is expected to contribute positively to Zimmer Biomet's mission of improving patient care and quality of life.
Read more →ZBHZimmer Biomet to Present at the 42nd Annual J.P. Morgan Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...
Zimmer Biomet Holdings, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The management team will discuss the company's innovative medical technologies and patient solutions. A live webcast of the presentation will be available on their Investor Relations website, with an archived replay option.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2023 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the fourth quarter of 2023. This dividend is payable on January 31, 2024, to stockholders of record by December 27, 2023. The company emphasizes its dedication to enhancing patient experiences through innovative medical technologies.
Read more →ZBHZimmer Biomet to Present at the 2023 Piper Sandler Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...
Zimmer Biomet Holdings, Inc. will present at the 2023 Piper Sandler Healthcare Conference on November 30, 2023. The presentation will be accessible via a live webcast on their Investor Relations website. This event highlights Zimmer Biomet's commitment to innovation in medical technology and patient care.
Read more →ZBHZimmer Biomet Announces Third Quarter 2023 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2023. The Company reported...
Zimmer Biomet Holdings, Inc. reported a strong financial performance for the third quarter of 2023, with net sales reaching $1.754 billion, a 5.0% increase compared to the previous year. The company reaffirmed its revenue guidance for the year, despite some challenges in international sales, particularly in the hips category. The new CEO, Ivan Tornos, expressed confidence in the company's growth trajectory moving forward.
Read more →ZBHMedia Investors Meredith Weissman Zach Weiner (703) 346-3127 (908) 591-6955 meredith.weissman@zimmerbiomet.com zach.weiner@zimmerbiomet.com Heather Zoumas-Lubeski (445) 248-0577 heather.zoumaslubeski@zimmerbiomet.com Zim
Zimmer Biomet Holdings, Inc. reported its third quarter 2023 financial results, achieving net sales of $1.754 billion, a 5.0% increase year-over-year. The company also announced a diluted earnings per share of $0.77, while adjusted diluted EPS reached $1.65. CEO Ivan Tornos expressed confidence in continued growth and the company updated its 2023 revenue guidance amid currency fluctuations. Zimmer Biomet also highlighted leadership changes and the successful enrollment of 100,000 patients in its mymobility platform.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of Third Quarter 2023 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Tuesday, November 7,...
Zimmer Biomet Holdings, Inc. has announced a webcast for its third quarter 2023 earnings conference call, scheduled for November 7, 2023. The call will begin at 8:30 a.m. ET, with a news release available earlier that day. Investors can join via phone or through the company's Investor Relations website.
Read more →ZBHZimmer Biomet Announces Key Updates to Company's Executive Leadership Team Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced key updates to the Company's Executive...
Zimmer Biomet has announced significant updates to its Executive Leadership Team, promoting Wilfred van Zuilen to Group President for EMEA and Mark Bezjak to President of the Americas. Additionally, Dr. Nitin Goyal has been appointed to the Executive Leadership Team, emphasizing the company's commitment to innovation and commercial execution. These changes aim to enhance the company's strategic direction and stakeholder value.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Third Quarter of 2023 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the...
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the third quarter of 2023. This dividend is set to be paid on or about October 31, 2023, to stockholders of record by September 29, 2023. The announcement underscores the company's commitment to returning value to its shareholders.
Read more →ZBHZimmer Biomet to Present at the 2023 Wells Fargo Healthcare Conference Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management...
Zimmer Biomet Holdings, Inc. will present at the 2023 Wells Fargo Healthcare Conference on September 6, 2023. The presentation will be accessible via a live webcast and will be archived for later viewing. The company emphasizes its commitment to innovation and improving patient experiences through advanced technologies.
Read more →ZBHZimmer Biomet Announces Leadership Transition Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced the appointment of Ivan Tornos as President and Chief Executive Officer (CEO) and...
Zimmer Biomet has appointed Ivan Tornos as the new President and CEO, effective immediately, succeeding Bryan Hanson. Tornos, previously the Chief Operating Officer, has a strong background in the medtech industry. The company also expanded Suketu Upadhyay's role to include oversight of global operations and reaffirmed its financial guidance for 2023.
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Heather Zoumas-Lubeski (445) 2
Zimmer Biomet has appointed Ivan Tornos as President and CEO, succeeding Bryan Hanson who is leaving for another CEO role. Tornos, who was previously the COO, aims to accelerate growth and innovation in the musculoskeletal care sector. CFO Suky Upadhyay's role has expanded to include oversight of global operations and supply chain. The company reaffirmed its financial guidance for 2023 amidst this leadership transition.
Read more →ZBHZimmer Biomet Announces Second Quarter 2023 Financial Results Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2023. The Company reported second...
Zimmer Biomet Holdings, Inc. reported strong financial results for Q2 2023, with net sales of $1.870 billion, reflecting a 4.9% increase from the previous year. The company also achieved diluted earnings per share of $1.00, with adjusted earnings of $1.82. In light of its performance, Zimmer Biomet has raised its financial guidance for the remainder of 2023, citing confidence in its business and innovation pipeline.
Read more →ZBHMedia Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 heather.zoumasl
Zimmer Biomet reported strong financial results for the first quarter of 2023, with net sales of $1.831 billion, reflecting a 10.1% increase year-over-year. The diluted earnings per share were reported at $1.11, with an adjusted figure of $1.89. The company has raised its full-year guidance, indicating confidence in continued growth driven by ongoing market recovery and innovation in medical technology. Key highlights include the launch of the Persona OsseoTi Keel Tibia and the acquisition of Embody, Inc., enhancing their offerings in sports medicine.
Read more →ZBHMedia Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Heather Zoumas-Lubeski (445) 248-0577 Heather.ZoumasLubeski@zimmerbiomet.com Zim
Zimmer Biomet reported its financial results for the fourth quarter and full year of 2022, showing a 2.7% increase in net sales for the quarter and a 1.6% increase for the full year. Despite these gains, the company faced a diluted loss per share of $0.62 in the fourth quarter. Looking into 2023, Zimmer Biomet provided financial guidance, projecting a revenue change of 1.5% to 3.5%. The company also announced recent innovations, including FDA clearance for a new knee replacement product and plans to acquire Embody, Inc. to enhance its portfolio in orthopedic solutions.
Read more →ZBHMedia Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biomet Announces Se
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biome
Read more →ZBHshould be read in conjunction with the 2021 Form 10-K and subsequent filings with the SEC, including our Form 10-Q for the quarter ended
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox 703-346-3127 215-275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci 617-549-2443 ezgi.yagci
www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox 703-346-3127 215-275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci 617-549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biomet Announces Appointment of New Chief Accounting Of
Read more →ZBHMedia Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biomet Announces Fi
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biome
Read more →ZBHAs previously announced, on
As previously announced, on March 1, 2022, Zimmer Biomet Holdings, Inc. (the "Company") completed the separation (the "Separation") of its spine and dental businesses through the distribution by the Company of 80.3% of the outstanding shares of common stock of ZimVie Inc. ("ZimVi
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biomet A
Read more →ZBH▼ -9.1%on this news
Investor Day
Investor Day February 7, 2022 Disclaimer FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES Safe Harbor Statement under the Private Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among
Read more →ZBH▼ -7.4%on this news
Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biomet Announces Th
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biome
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Contacts: Media Meredith Weissman (703) 346-3127 meredith.weissman@zimmerbiomet.com Investors Ezgi Yagci Keri Mattox (617) 549-2443 (203) 399-0856 ezgi.yagci@zimmerbiomet
www.zimmerbiomet.com meredith.weissman@zimmerbiomet.com Investors Ezgi Yagci Keri Mattox (617) 549-2443 (203) 399-0856 ezgi.yagci@zimmerbiomet.com keri.mattox@zimmerbiomet.com Zimmer Biomet Expands Role for Ivan Tornos, Appointing Him to New Chief Operating Officer Post
Read more →ZBHMedia Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biomet Announces Fo
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 meredith.weissman@zimmerbiomet.com keri.mattox@zimmerbiomet.com Ezgi Yagci (617) 549-2443 ezgi.yagci@zimmerbiomet.com Zimmer Biome
Read more →ZBHMedia Investors Monica Kendrick Keri Mattox (574) 373-2095 (215) 275-2431 monica.kendrick@zimmerbiomet.com keri.mattox@zimmerbiomet.com Barbara Goslee (574) 371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Announces F
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Monica Kendrick Keri Mattox (574) 373-2095 (215) 275-2431 monica.kendrick@zimmerbiomet.com keri.mattox@zimmerbiomet.com Barbara Goslee (574) 371-9449 barb.goslee@zimmerbiomet.com Zimmer Biom
Read more →ZBHMedia Investors Monica Kendrick Keri Mattox 574-373-2095 215-275-2431 monica.kendrick@zimmerbiomet.com keri.mattox@zimmerbiomet.com Barbara Goslee 574-371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Provides Update o
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Monica Kendrick Keri Mattox 574-373-2095 215-275-2431 monica.kendrick@zimmerbiomet.com keri.mattox@zimmerbiomet.com Barbara Goslee 574-371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Pro
Read more →ZBHMedia Investors Monica Kendrick Keri Mattox (574) 373-2095 (215) 275-2431 monica.kendrick@zimmerbiomet.com keri.mattox@zimmerbiomet.com Cole Lannum, CFA (508) 409-9366 cole.lannum@zimmerbiomet.com Zimmer Biomet Announces
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Monica Kendrick Keri Mattox (574) 373-2095 (215) 275-2431 monica.kendrick@zimmerbiomet.com keri.mattox@zimmerbiomet.com Cole Lannum, CFA (508) 409-9366 cole.lannum@zimmerbiomet.com Zimmer Bi
Read more →ZBHMedia Investors Wendy Wilson Cole Lannum, CFA (574) 373-3798 (508) 409-9366 wendy.wilson@zimmerbiomet.com cole.lannum@zimmerbiomet.com Barb Goslee (574) 371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Announces Third
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Wendy Wilson Cole Lannum, CFA (574) 373-3798 (508) 409-9366 wendy.wilson@zimmerbiomet.com cole.lannum@zimmerbiomet.com Barb Goslee (574) 371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet A
Read more →ZBHMedia Investors Wendy Wilson Cole Lannum, CFA (574) 373-3798 (574) 371-9480 wendy.wilson@zimmerbiomet.com cole.lannum@zimmerbiomet.com Barb Goslee (574) 371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Announces Secon
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Wendy Wilson Cole Lannum, CFA (574) 373-3798 (574) 371-9480 wendy.wilson@zimmerbiomet.com cole.lannum@zimmerbiomet.com Barb Goslee (574) 371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet A
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Contacts: Media Investors Wendy Wilson Cole Lannum 574-373-3798 574-371-9480 wendy.wilson@zimmerbiomet.com cole.lannum@zimmerbiomet.com Barbara Goslee 574-371-9449 barb.g
www.zimmerbiomet.com Media Investors Wendy Wilson Cole Lannum 574-373-3798 574-371-9480 wendy.wilson@zimmerbiomet.com cole.lannum@zimmerbiomet.com Barbara Goslee 574-371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Announces Chief Financial Officer Transition Plan Suk
Read more →ZBHMedia Investors Wendy Wilson Cole Lannum, CFA (574) 373-3798 (574) 371-9480 wendy.wilson@zimmerbiomet.com cole.lannum@zimmerbiomet.com Barb Goslee (574) 371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Announces First
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Wendy Wilson Cole Lannum, CFA (574) 373-3798 (574) 371-9480 wendy.wilson@zimmerbiomet.com cole.lannum@zimmerbiomet.com Barb Goslee (574) 371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet A
Read more →ZBHMedia Investors Monica Kendrick Coleman Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Barb Goslee (574) 371-9449 Barb.Goslee@ZimmerBiomet.com Zimmer Biomet Announces F
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Monica Kendrick Coleman Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Barb Goslee (574) 371-9449 Barb.Goslee@ZimmerBiomet.com Zimmer Biom
Read more →ZBHMedia Investors Monica Kendrick Coleman Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Derek Davis (574) 372-4250 Derek.Davis@ZimmerBiomet.com Zimmer Biomet Announces T
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Monica Kendrick Coleman Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Derek Davis (574) 372-4250 Derek.Davis@ZimmerBiomet.com Zimmer Biom
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Contacts: Media Investors Monica Kendrick 574-372-4989 Coleman Lannum 574-371-9480 monica.kendrick@zimmerbiomet.com cole.lannum@zimmerbiomet.com Derek Davis 574-372-4250
www.zimmerbiomet.com Media Investors Monica Kendrick 574-372-4989 Coleman Lannum 574-371-9480 monica.kendrick@zimmerbiomet.com cole.lannum@zimmerbiomet.com Zimmer Biomet Appoints Maria Teresa (Tessa) Hilado and Syed Jafry to Board of Directors Hilado and Jafry Bring Financ
Read more →ZBHMedia Investors Monica Kendrick Coleman Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Derek Davis (574) 372-4250 Derek.Davis@ZimmerBiomet.com Zimmer Biomet Announces S
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Monica Kendrick Coleman Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Derek Davis (574) 372-4250 Derek.Davis@ZimmerBiomet.com Zimmer Biom
Read more →ZBHMedia Investors Monica Kendrick Coleman Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Derek Davis (574) 372-4250 Derek.Davis@ZimmerBiomet.com Zimmer Biomet Announces F
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Monica Kendrick Coleman Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Derek Davis (574) 372-4250 Derek.Davis@ZimmerBiomet.com Zimmer Biom
Read more →ZBHMedia Investors Monica Kendrick Cole Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Derek Davis (574) 372-4250 Derek.Davis@ZimmerBiomet.com Barbara Goslee (574) 371-944
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Monica Kendrick Cole Lannum (574) 372-4989 (574) 371-9480 Monica.Kendrick@ZimmerBiomet.com Cole.Lannum@ZimmerBiomet.com Derek Davis (574) 372-4250 Derek.Davis@ZimmerBiomet.com Barbara Goslee
Read more →ZBHCALCULATION AGENT AGREEMENT This Calculation Agent Agreement (this Agreement ) is entered into as of
CALCULATION AGENT AGREEMENT This Calculation Agent Agreement (this Agreement ) is entered into as of March 19, 2018 by and between Zimmer Biomet Holdings, Inc., a Delaware corporation (the Company ), and Wells Fargo Bank, National Association, a national banking association, as
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Contacts: Media Investors Monica Kendrick Derek Davis (574) 372-4989 (574) 372-4250 monica.kendrick@zimmerbiomet.com derek.davis@zimmerbiomet.com Barbara Goslee (574) 371
www.zimmerbiomet.com Media Investors Monica Kendrick Derek Davis (574) 372-4989 (574) 372-4250 monica.kendrick@zimmerbiomet.com derek.davis@zimmerbiomet.com Barbara Goslee (574) 371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Prices Offering of Senior Notes (WARS
Read more →ZBHMedia Investors Monica Kendrick Derek Davis (574) 372-4989 (574) 372-4250 Monica.Kendrick@ZimmerBiomet.com Derek.Davis@ZimmerBiomet.com Barbara Goslee (574) 371-9449 Barb.Goslee@ZimmerBiomet.com Zimmer Biomet Announces F
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Monica Kendrick Derek Davis (574) 372-4989 (574) 372-4250 Monica.Kendrick@ZimmerBiomet.com Derek.Davis@ZimmerBiomet.com Barbara Goslee (574) 371-9449 Barb.Goslee@ZimmerBiomet.com Zimmer Biom
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Contacts: Monica Kendrick Derek Davis 574-372-4989 574-372-4250 monica.kendrick@zimmerbiomet.com derek.davis@zimmerbiomet.com Barbara Goslee 574-371-9449 barb.goslee@zimm
www.zimmerbiomet.com Monica Kendrick Derek Davis 574-372-4989 574-372-4250 monica.kendrick@zimmerbiomet.com derek.davis@zimmerbiomet.com Barbara Goslee 574-371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Announces Appointment of Bryan C. Hanson as President and Chief
Read more →ZBHE. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Monica Kendrick Matt Abernethy 574-372-4989 574-371-8042 monica.kendrick@zimmerbiomet.com matt.abernethy@zimmerbiomet.com Barbara Goslee 574-371-9449 barb
345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Monica Kendrick Matt Abernethy 574-372-4989 574-371-8042 monica.kendrick@zimmerbiomet.com matt.abernethy@zimmerbiomet.com Barbara Goslee 574-371-9449 barb.goslee@zimmerbiomet.com Zimmer Biomet Reports T
Read more →Competitive Position
How ZBH ranks across every disease it competes inCompetitive Position is a premium feature
See how ZBH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial